Related Experiment Videos
Metoprolol in acute myocardial infarction. Mortality. The MIAMI Trial Research Group
Abstract:
After 15 days there were 142 deaths in the placebo group (4.9%) and 123 deaths in the metoprolol group (4.3%), a difference of 13% (p = 0.29). The 95% confidence limits for the relative effect of metoprolol ranged from an 8% excess (-8%) to a 33% reduction (+33%) in mortality. There was generally a lower mortality rate for metoprolol-treated patients in most subgroups and a consistent tendency for a more pronounced difference between the treatment groups in those subgroups with a placebo mortality rate higher than the average for all placebo patients. Most deaths were cardiac and occurred among patients who developed a definite myocardial infarction (97%) and most of these had a Q-wave infarction (83%). Using a simple model, the placebo mortality was found to increase with increasing number of 8 risk predictors defined from prestudy experience, from 0% in patients with no risk predictors to 11.6% in patients with any 5 or more of these risk factors. Similarly, there was an increase in the difference between the treatment groups in favor of metoprolol with increasing number of placebo risk factors. Metoprolol had no apparent effect in a low-mortality risk group (less than or equal to 2 risk factors), but there was a difference in mortality of 29% in favor of metoprolol in a high-risk group (greater than or equal to 3 risk factors) comprising one-third of the trial population.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Metoprolol showed a trend towards lower mortality in heart attack patients, particularly benefiting those with higher risk factors. The drug demonstrated a significant mortality reduction in high-risk individuals.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Myocardial infarction (MI) is a leading cause of mortality.
- Identifying effective treatments to reduce post-MI mortality is crucial.
- Beta-blockers like metoprolol are commonly used post-MI.
Purpose of the Study:
- To evaluate the efficacy of metoprolol in reducing mortality after myocardial infarction.
- To assess the effect of metoprolol across different patient risk subgroups.
Main Methods:
- A randomized controlled trial comparing metoprolol to placebo in post-MI patients.
- Mortality and cardiac events were tracked for 15 days.
- Analysis included subgroup comparisons based on pre-study risk factors.
Main Results:
- Overall mortality was 4.3% with metoprolol vs. 4.9% with placebo (p=0.29).
- Metoprolol showed a trend towards reduced mortality, especially in patients with higher baseline risk.
- A significant 29% mortality reduction was observed in high-risk patients (≥3 risk factors).
Conclusions:
- Metoprolol may offer a survival benefit in post-myocardial infarction patients, particularly those at high risk.
- Risk stratification is important for identifying patients most likely to benefit from metoprolol treatment.
- Further research may explore long-term outcomes and optimal use in specific risk groups.